A private company taking a unique approach to treating inflammatory diseases like rheumatoid arthritis (RA) and Crohn's disease has attracted new financial support in the form of a $15 million extension to its Series C financing, bringing the total of the round to $43 million.

Pharmaceutical company Allergan (Dublin) spotted an opportunity to add an implantable shunt technology to its eye care offering through a $300 million cash acquisition of privately held Aquesys (Aliso Viejo, Calif.). The deal also includes regulatory and commercialization payments for an undisclosed amount. Aquesys' lead product is XEN45, a soft shunt that is implanted in the subconjunctival space in the eye through a minimally invasive procedure with a single use, pre-loaded injector. The deal is expected to close in 4Q15.

Allergan plc spotted an opportunity to add an implantable shunt technology to its eye care offering through a $300 million cash acquisition of privately held Aquesys Inc., of Aliso Viejo, Calif.

Medtronic (Dublin) appears to be making good on its promise to invest in and acquire U.S. medical technology following its $42.9 billion purchase of Covidien. The company just acquired Medina Medical (Menlo Park, Calif.), a private firm it already had an ownership stake in, for $150 million plus milestone-based payments.